Goldman Sachs’s Agile Therapeutics, Inc AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-12
| Closed | -$12K | – | 6004 |
|
|
2021
Q4 | $12K | Buy |
+12
| New | +$12K | ﹤0.01% | 5495 |
|
|
2021
Q3 | – | Sell |
-114
| Closed | -$305K | – | 5606 |
|
|
2021
Q2 | $305K | Buy |
114
+97
| +571% | +$260K | ﹤0.01% | 4697 |
|
|
2021
Q1 | $73K | Buy |
17
+8
| +89% | +$34.4K | ﹤0.01% | 5088 |
|
|
2020
Q4 | $50K | Sell |
9
-1
| -10% | -$5.56K | ﹤0.01% | 4563 |
|
|
2020
Q3 | $62K | Buy |
+10
| New | +$62K | ﹤0.01% | 4296 |
|
|
2020
Q2 | – | Sell |
-32
| Closed | -$118K | – | 4607 |
|
|
2020
Q1 | $118K | Buy |
+32
| New | +$118K | ﹤0.01% | 4131 |
|
|
2018
Q2 | – | Sell |
-7
| Closed | -$34K | – | 4368 |
|
|
2018
Q1 | $34K | Sell |
7
-1
| -13% | -$4.86K | ﹤0.01% | 4117 |
|
|
2017
Q4 | $41K | Buy |
+8
| New | +$41K | ﹤0.01% | 4050 |
|
|
2017
Q3 | – | Sell |
-41
| Closed | -$309K | – | 4463 |
|
|
2017
Q2 | $309K | Buy |
+41
| New | +$309K | ﹤0.01% | 3781 |
|
|
2015
Q3 | – | Sell |
-24
| Closed | -$405K | – | 4737 |
|
|
2015
Q2 | $405K | Sell |
24
-8
| -25% | -$135K | ﹤0.01% | 3493 |
|
|
2015
Q1 | $597K | Buy |
32
+4
| +14% | +$74.6K | ﹤0.01% | 3203 |
|
|
2014
Q4 | $348K | Sell |
28
-14
| -33% | -$174K | ﹤0.01% | 3595 |
|
|
2014
Q3 | $612K | Buy |
42
+31
| +282% | +$452K | ﹤0.01% | 3211 |
|
|
2014
Q2 | $194K | Buy |
+11
| New | +$194K | ﹤0.01% | 3990 |
|